受注:045-509-1970 |
技術サポート:[email protected] 平日9:00〜18:00 1営業日以内にご連絡を差し上げます |
Synonyms | Xyzal Dihydrochloride, (-)-Cetirizine Dihydrochloride | Storage (From the date of receipt) |
3 years -20°C powder 1 years -80°C in solvent |
|
化学式 | C21H25ClN2O3.2HCl |
|||
分子量 | 461.81 | CAS No. | 130018-87-0 | |
Solubility (25°C)* | 体外 | DMSO | 92 mg/mL (199.21 mM) | |
Water | 92 mg/mL (199.21 mM) | |||
Ethanol | 7 mg/mL (15.15 mM) | |||
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
製品説明 | Levocetirizine (Xyzal, (-)-Cetirizine) is the active R-enantiomer of cetirizine and represents a new second-generation histamine H1 antagonist. |
---|---|
in vitro | Levocetirizine is a selective antihistaminic that acts through H1 receptor. Levocetirizine inhibits eotaxin-induced eosinophil transendothelial migration through monolayers of human dermal or lung microvascular endothelial cells in vitro. The drug also inhibits both resting and granulocyte-macrophage colony-stimulating factor (GM-CSF)-stimulated eosinophil adhesion to vascular cell adhesion molecule-1 (VCAM-1), eotaxin production by endothelial cells and ICAM-1, as well as major histocompatability complex (MHC) class I expression by interferon (IFN)-γ-stimulated keratinocytes[1]. |
in vivo | In vivo, levocetirizine has rapid absorption and high bioavailability, a low potential for drug interactions, low-volume distribution and a lack of effects on cognition, psychomotor function or the cardiovascular system[1]. Levocetirizine improves renal function in diabetic rat. It attenuates the elevated renal levels of TNF-α and TGF-β1, ameliorates renal oxidative stress and restores NO bioavailability in diabetic kidney. Levocetirizine elicits vasculoprotective and renoprotective effects in experimental diabetes[2]. |
動物実験 | 動物モデル | Male Sprague Dawley rats (with diabetes induced by STZ) |
---|---|---|
投薬量 | 0.5 mg/kg/day | |
投与方法 | orally |
|
Histamine Receptor Antagonists, Loratadine and Azelastine, Sensitize P-gp-overexpressing Antimitotic Drug-resistant KBV20C Cells Through Different Molecular Mechanisms. [ Anticancer Res, 2019, 39(7):3767-3775] | PubMed: 31262903 |
長期の保管のために-20°Cの下で製品を保ってください。
人間や獣医の診断であるか治療的な使用のためにでない。
各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。